Sugi Predict

Sugi Predict / Compounds / SCHEMBL113242

SCHEMBL113242

SCHEMBL113242

Cc1cc(C)n(CC(=O)O)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 1.00
▸ ALDH1A1 P00352 3/20 0.66
▸ KDM4E B2RXH2 3/20 0.64
▸ PKM P14618 1/20 0.64
▸ APAF1 O14727 1/20 0.59
▸ POLB P06746 1/20 0.59
▸ RAB9A P51151 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ GLA P06280 1/20 0.52
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ HTT P42858 1/20 0.50
▸ GLS O94925 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7788141 0.84 LMNA (0.72) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL4522189 0.82 LMNA (0.70) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL15581474 0.82 LMNA (0.70) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL11228049 0.82 LMNA (0.70) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL4934431 0.82 LMNA (0.70) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL18754429 0.81 LMNA (0.68) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL14097078 0.81 LMNA (0.68) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL11783550 0.81 LMNA (0.68) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL855066 0.81 KDM4E (0.81) LMNAALDH1A1KDM4EPKMAPAF1
SCHEMBL8017055 0.81 LMNA (0.68) LMNAALDH1A1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522618-B2 Copper complexes for treatment of neurodegenerative disorders ALS THERAPY DEVELOPMENT INSTITUTE (US) 2026-01-13 — — US disclosed
US-20240368195-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS ALS THERAPY DEVELOPMENT INST (US) 2024-11-07 — — US disclosed
US-12012422-B2 Copper complexes for treatment of neurodegenerative disorders ALS THERAPY DEVELOPMENT INSTITUTE (US) 2024-06-18 — — US disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 — — US disclosed
EP-4204399-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS ALS Therapy Development Institute (US) 2023-07-05 — — EP disclosed
CN-116234800-A Copper complexes for the treatment of neurodegenerative disorders ALS治疗发展学会 2023-06-06 — — CN disclosed
US-20230087342-A1 AZEPANE DERIVATIVE NIPPON CHEMIPHAR CO., LTD. (JP) 2023-03-23 — — US disclosed
US-20230054997-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS ALS THERAPY DEVELOPMENT INSTITUTE, 2023-02-23 — — US disclosed
WO-2022210479-A1 USE OF AZEPANE DERIVATIVE FOR TREATMENT, AMELIORATION OR PREVENTION OF κ-OPIOID RECEPTOR-RELATED DISEASES 日本ケミファ株式会社 2022-10-06 — — WO disclosed
EP-4039331-A1 AZEPAN DERIVATIVE Nippon Chemiphar Co., Ltd. (JP) 2022-08-10 — — EP disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 — — WO disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 — — WO disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 — — WO disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 — — WO disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 — — US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 — — US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 — — US disclosed
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 — — US disclosed
EP-1962605-A2 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS Merck & Co., Inc. (US) 2008-09-03 — — EP disclosed
WO-2007070433-A2 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012422-B2 Copper complexes for treatment of neurodegenerative disorders SOD1, SMN1; SMN2, CLN6 LMNA 1550/4885ALDH1A1 1721/4885KDM4E 3459/4885
US-20230054997-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SOD1, SMN1; SMN2, CLN6 LMNA 1550/4885ALDH1A1 1721/4885KDM4E 3459/4885
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 LMNA 3021/4885ALDH1A1 2556/4885KDM4E 1156/4885
US-20230087342-A1 AZEPANE DERIVATIVE ADCY10, AZI2, PRMT1 LMNA 4336/4885ALDH1A1 1400/4885KDM4E 1089/4885
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 LMNA 3677/4885ALDH1A1 1720/4885KDM4E 3738/4885
US-20240368195-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SOD1, SMN1; SMN2, CLN6 LMNA 1550/4885ALDH1A1 1721/4885KDM4E 3459/4885
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators CXCR3, CXCR1, CXCR5 LMNA 4866/4885ALDH1A1 1431/4885KDM4E 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.